B
BioSpace
Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
0:00-24:18
New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this week, including Novartis’ nearly $8 billion bet on mRNA drugs with China’s Abogen Biosciences; and could Sarepta Therapeutics turn things around from last year’s annus horribilis?
Publisher
BioSpace
Published
October 7, 2026
Duration
24 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
B
BioSpace
@biospace
#genmab #abbviesepkinlywin #sareptasturnaroundhopes #lifesciences
